Decision analytic models for Alzheimer's disease: State of the art and future directions

Alzheimer's and Dementia

Volumn 4, Issue 3, 2008, Pages 212-222

  Cohen, Joshua T ^a   Neumann, Peter J ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness; Decision analysis; Disease progression; Pharmacoeconomics; Simulation

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; FLUORODEOXYGLUCOSE; FOLIC ACID; GALANTAMINE; MEMANTINE; RIVASTIGMINE; SIMVASTATIN; TACRINE;

ALZHEIMER DISEASE; ARTICLE; CANCER INCIDENCE; CANCER SCREENING; CAREGIVER BURDEN; CAREGIVER SUPPORT; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; EMPIRICAL RESEARCH; HEALTH CARE COST; HEALTH CARE POLICY; HEART DISEASE; HUMAN; NEURAL TUBE DEFECT; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESIDENTIAL AREA; SCREENING TEST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL MODEL; THYROID CANCER; UNCERTAINTY; UTERINE CERVIX CANCER;

ALZHEIMER DISEASE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; ECONOMICS, PHARMACEUTICAL; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 43649100201     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2008.02.003     Document Type: Article

References (84)

1. Hu T.W., Huang L.F., and Cartwright W.S. Evaluation of the costs of caring for the senile demented elderly: a pilot study. Gerontologist 26 (1986) 158-163
2. Hay J.W., and Ernst R.L. The economic costs of Alzheimer's disease. Am J Public Health 77 (1987) 1169-1175
3. Huang L.F., Cartwright W.S., and Hu T.W. The economic cost of senile dementia in the United States, 1985. Public Health Rep 103 (1988) 3-7
4. Leon J., Cheng C.K., and Neumann P.J. Alzheimer's disease care: costs and potential savings. Health Affairs 17 (1998) 206-216
5. Hauber A.B., Gnanasakthy A., and Mauskopf J.A. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine. Clin Ther 22 (2000) 439-451
6. Kinosian B.P., Stallard E., Lee J.H., Woodbury M.A., Zbrozek A.S., and Glick H.A. Predicting 10-year care requirements for older people with suspected Alzheimer's disease. J AmGeriatr Soc 48 (2000) 631-638
7. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., and Evans D.A. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60 (2003) 1119-1122
8. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-effectiveness in health and medicine (1996), Oxford University Press, Oxford, UK
9. Weinstein M.C., Toy E.L., Sandberg E.A., Neumann P.J., Evans J.S., Kuntz K.M., et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 4 (2001) 348-361
10. Drachman D.A., O'Donnell B.F., Lew R.A., and Swearer J.M. The prognosis in Alzheimer's disease: 'how far' rather than 'how fast' best predicts the course. Arch Neurol 47 (1990) 851-856
11. Mortimer J.A., Ebbitt B., Jun S.P., and Finch M.D. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 42 (1992) 1689-1696
12. Brodaty H., McGilchrist C., Harris L., and Peters K.E. Time until institutionalization and death in patients with dementia: role of caregiver training and risk factors. Arch Neurol 50 (1993) 643-650
13. Cohen C.A., Gold D.P., Shulman K.I., Wortley J.T., McDonald G., and Wargon M. Factors determining the decision to institutionalize dementing individuals: a prospective study. Gerontologist 33 (1993) 714-720
14. Kraemer H.C., Tinklenberg J., and Yesavage J.A. 'How far' vs 'how fast' in Alzheimer's disease: the question revisited. Arch Neurol 51 (1994) 275-279
15. Stern R.G., Mohs R.C., Davidson M., Schmeidler J., Silverman J., Kramer-Ginsberg E., et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 151 (1994) 390-396
16. Heyman A., Peterson B., Fillenbaum G., and Pieper C. Predictors of time to institutionalization of patients with Alzheimer's disease: the CERAD experience, part XVII. Neurology 48 (1997) 1304-1309
17. Stern Y., Tang M.X., Albert M.S., Brandt J., Jacobs D.M., Bell K., et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 277 (1997) 806-812
18. Knopman D.S., Berg J.D., Thomas R., Grundman M., Thal L.J., and Sano M. Nursing home placement is related to dementia progression: experience from a clinical trial: Alzheimer's Disease Cooperative Study. Neurology 52 (1999) 714-718
19. Rasmussen D.X., Carson K.A., Brookmeyer R., Kawas C., and Brandt J. Predicting the rate of decline in probably Alzheimer's disease. Brain Cogn 31 (1996) 133-147
20. Neumann P.J., Hermann R.C., Kuntz K.M., Araki S.S., Duff S.B., Leon J., et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 52 (1999) 1138-1145
21. Claxton K., Neumann P.J., Araki S., and Weinstein M.C. Bayesian value-of-information analysis. an application to a policy model of Alzheimer's disease. Int J Technol Assess Health Care 17 (2001) 38-55
22. McMahon P.M., Araki S.S., Neumann P.J., Harris G.J., and Gazelle G.S. Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. Radiology 217 (2000) 58-68
23. McMahon P.M., Araki S.S., Sandberg E.A., Neumann P.J., and Gazelle G.S. Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology 228 (2003) 515-522
24. Wimo A., Winblad B., Engedal K., Soininen H., Verhey F., Waldemar G., et al. An economic evaluation of donepezil in mild to moderate Alzeimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 15 (2003) 44-54
25. Aguero-Torres H., Hilleras P.K., and Winblad B. Disability in activities of daily living among the elderly. Geriatr Psychiatry 14 (2001) 355-359
26. Gilley D.W., Bienias J.L., Wilson R.S., Bennett D.A., Beck T.L., and Evans D.A. Influence of behavioral symptoms on rates of institutionalization for persons with Alzheimer's disease. Psychol Med 34 (2004) 1129-1135
27. Yaffe K., Fox P., Newcomer R., Sands L., Lindquist K., Dane K., et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 287 (2002) 2090-2097
28. Hux M.J., O'Brien B.J., Iskedjian M., Goeree R., Gagnon M., and Gauthier S. Relation between severity of Alzheimer's disease and costs of caring. CMAJ 159 (1998) 457-465
29. Murman D.L., Chen Q., Powell M.C., Kuo S.B., Bradley C.J., and Colenda C.C. The incremental direct costs associated with behavioral symptoms in AD. Neurology 59 (2002) 1721-1729
30. Moore M.J., Zhu C.W., and Clipp E.C. Informal costs of dementia care: estimates from the National Longitudinal Caregiver Study. J Gerontol B Psychol Sci Soc Sci 56 (2001) S219-S228
31. Small G.W., McDonnell D.D., Brooks R.L., and Papadopoulos G. The impact of symptom severity on the cost of Alzheimer's disease. J Am Geriatr Soc 50 (2002) 321-327
32. Murman D.L., Kuo S.B., Powell M.C., and Colenda C.C. The impact of parkinsonism on costs of care in patients with AD and dementia with Lewy bodies. Neurology 61 (2003) 944-949
33. Feldman H.H., Van B.B., Kavanagh S.M., and Torfs K.E. Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysis. Alzheimer Dis Assoc Disord 19 (2005) 29-36
34. Kulasingam S.L., Samsa G.P., Zarin D.A., Rutschmann O.T., Patwardhan M.B., McCrory D.C., et al. When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia?. a decision analysis. Value Health 6 (2003) 542-550
35. Caro J.J., Getsios D., Migliaccio-Walle K., Raggio G., and Ward A. Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care. Neurology 57 (2001) 964-971
36. Jones R.W., McCrone P., and Guilhaume C. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging 21 (2004) 607-620
37. Henke C.J., and Burchmore M.J. The economic impact of the tacrine in the treatment of Alzheimer's disease. Clin Ther 19 (1997) 330-345
38. Stewart A., Phillips R., and Dempsey G. Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Int J Geriatr Psychiatry 13 (1998) 445-453
39. Jonsson L., Lindgren P., Wimo A., Jonsson B., and Winblad B. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clinl Ther 21 (1999) 1230-1240
40. O'Brien B.J., Goeree R., Hux M., Iskedjian M., Blackhouse G., Gagnon M., et al. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 47 (1999) 570-578
41. Wimo A., Karlsson G., Nordberg A., and Winblad B. Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alzheimer Dis Assoc Disord 11 (1997) 191-200
42. McDonnell J., Redekop W.K., van der Roer N., Goes E., Ruitenberg A., Busschbach J.J.V., et al. The cost of treatment of Alzheimer's disease in The Netherlands: a regression based simulation model. Pharmacoeconomics 19 (2001) 379-390
43. Fenn P., and Gray A. Estimating long-term cost savings from treatment of Alzheimer's disease: a modelling approach. Pharmacoeconomics 16 (1999) 165-174
44. Fagnani F., Lafuma A., Pechevis M., Rigaud A.S., Traykov L., Seux M.L., et al. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications. Dement Geriatr Cogn Disord 17 (2004) 5-13
45. Martikainen J., Valtonen H., and Pirttila T. Potential cost-effectiveness of a family-based program in mild Alzheimer's disease patients. Eur J Health Econ 5 (2004) 136-142
46. Murman D.L., Von E.A., Sherwood P.R., Liang J., and Colenda C.C. Evaluated need, costs of care, and payer perspective in degenerative dementia patients cared for in the United States. Alzheimer Dis Assoc Disord 21 (2007) 39-48
47. Loveman E., Green C., Kirby J., Takeda A., Picot J., Payne E., et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 10 (2006) iii-xi 1
48. Caro J.J. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 23 (2005) 323-332
49. US Preventive Services Task Force. Dementia screening. 2003 (2004). http://www.ahrq.gov/clinic/uspstf/uspsdeme.htm Accessed: March 6, 2008
50. Fillit H.M., Doody R.S., Binaso K., Crooks G.M., Ferris S.H., Farlow M.R., et al. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother 4 Suppl A (2006) S9-S24
51. Caro J., Salas M., Ward A., Getsios D., and Mehnert A. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dement Geriatr Cogn Disord 14 (2002) 84-89
52. Migliaccio-Walle K., Getsios D., Caro J.J., Ishak K.J., O'Brien J.A., and Papadopoulos G. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther 25 (2003) 1806-1825
53. Ward A., Caro J.J., Getsios D., Ishak K., O'Brien J., and Bullock R. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry 18 (2003) 740-747
54. Caro J., Salas M., Ward A., Getsios D., Migliaccio-Walle K., and Garfield F. Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries. Drugs Aging 21 (2004) 677-686
55. Petersen R.C. Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia 15 (2000) 93-101
56. Grundman M., Petersen R.C., Ferris S.H., Thomas R.G., Aisen P.S., Bennett D.A., et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 61 (2004) 59-66
57. Larrieu S., Letenneur L., Orgogozo J.M., Fabrigoule C., Amieva H., Le Carret N., et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 59 (2002) 1594-1599
58. Morris J.C., Weintraub S., Chui H.C., Cummings J., Decarli C., Ferris S., et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 20 (2006) 210-216
59. Steele C., Rovner B., Chase G.A., and Folstein M.F. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 147 (1990) 1049-1051
60. Galasko D., Corey-Bloom J., and Thal L.J. Monitoring progression in Alzheimer's disease. J Am Geriatr Soc 39 (1991) 932-941
61. Drachman D.A., Swearer J.M., O'Donnell B.F., Mitchell A.L., and Maloon A. The Caretaker Obstreperous-Behavior Rating Assessment (COBRA) Scale. J Am Geriatr Soc 40 (1992) 463-470
62. Mega M.S., Cummings J.L., Fiorello T., and Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 46 (1996) 130-135
63. Jost B.C., and Grossberg G.T. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc 44 (1996) 1078-1081
64. Devanand D.P. Behavioral complications and their treatment in Alzheimer's disease. Geriatrics 52 Suppl 2 (1997) 37-39
65. Lopez O.L., Wisniewski S.R., Becker J.T., Boller F., and DeKosky S.T. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 56 (1999) 1266-1272
66. Getsios D., Caro J.J., Caro G., and Ishak K. Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada. Neurology 57 (2001) 972-978
67. Hill J.W., Futterman R., Duttagupta S., Mastey V., Lloyd J.R., and Fillit H. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Neurology 58 (2002) 62-70
68. Fillenbaum G., Heyman A., Peterson B.L., Pieper C.F., and Weiman A.L. Use and cost of outpatient visits of AD patients: CERAD XXII. Neurology 56 (2001) 1706-1711
69. Fillenbaum G., Heyman A., Peterson B.L., Pieper C.F., and Weiman A.L. Use and cost of hospitalization of patients with AD by stage and living arrangement: CERAD XXI. Neurology 56 (2001) 201-206
70. Ball K., Berch D.B., Helmers K.F., Jobe J.B., Leveck M.D., Marsiske M., et al. Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA 288 (2002) 2271-2281
71. Burns R., Nichols L.O., Martindale-Adams J., Graney M.J., and Lummus A. Primary care interventions for dementia caregivers: 2-year outcomes from the REACH study. Gerontologist 43 (2003) 547-555
72. Fillit H., and Hill J. The costs of vascular dementia: a comparison with Alzheimer's disease. J Neurosurg Sci 203-204 (2002) 35-39
73. Fillit H., Hill J.W., and Futterman R. Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy. Fam Med 34 (2002) 528-535
74. McCarty H.J., Roth D.L., Goode K.T., Owen J.E., Harrell L., Donovan K., et al. Longitudinal course of behavioral problems during Alzheimer's disease: linear versus curvilinear patterns of decline. J Gerontol A Biol Sci Med Sci 55 (2000) M200-M206
75. Mendiondo M.S., Ashford J.W., Kryscio R.J., and Schmitt F.A. Modelling mini mental state examination changes in Alzheimer's disease. Stat Med 19 (2000) 1607-1616
76. Suh G.H., Ju Y.S., Yeon B.K., Shah A., et al. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. Int J Geriatr Psychiatry 19 (2004) 817-824
77. Green C. Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis. Pharmacoeconomics 25 (2007) 735-750
78. Hauber A.B., Gnanasakthy A., Snyder E.H., Bala M.V., Richter A., and Mauskopf J.A. Potential savings in the cost of caring for Alzheimer's disease: treatment with rivastigmine. Pharmacoeconomics 17 (2000) 351-360
79. Marin D., Amaya K., Casciano R., Puder K.L., Casciano J., Chang S., et al. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease. Int Psychogeriatr 15 (2003) 385-398
80. Ikeda S., Yamada Y., and Ikegami N. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan. Dement Geriatr Cogn Disord 13 (2002) 33-39
81. Garfield F.B., Getsios D., Caro J.J., Wimo A., and Winblad B. Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden. Pharmacoeconomics 20 (2002) 629-637
82. Green C., Picot J., Loveman E., Takeda A., Kirby J., and Clegg A. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease. Pharmacoeconomics 23 (2005) 1271-1282
83. Antonanzas F., Rive B., Badenas J.M., Gomez-Lus S., and Guilhaume C. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: an adaptation in Spain. Eur J Health Econ 7 (2006) 137-144
84. Jonsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. Am J Geriatr Pharmacother 3 (2005) 77-86